Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Celgene
M.D. Anderson Cancer Center
Mayo Clinic
Stanford University
Mayo Clinic
Gilead Sciences
Pfizer
Array BioPharma
University of Arkansas
University of Arkansas
University Hospital Carl Gustav Carus
Universitätsklinikum Hamburg-Eppendorf